Psychology Today: Are You What You Eat?:
"...it's tempting to dwell on relationships between a particular food and a corresponding mental benefit or mood boost. But it's an overall healthy eating pattern that yields results, not any one food, warns Larry Lindner, executive editor of Tufts University's Health and Nutrition Newsletter. A diet rich in fruits, vegetables and dairy, for example, can blunt cognitive deficits in most people. But to those who say that eating a piece of bread raises serotonin levels and makes you happy, Lindner responds, "If carbohydrates caused happiness, ours would be the happiest nation in the world."

Each of us processes food in a unique way, too. "Some people have different metabolic rates," says neuroscientist Chandan Prasad, editor-in-chief of the journal Nutritional Neuroscience. "Even rats show individual effects in food studies." He points to the burgeoning field of genomics, where scientists are searching for links between genetic makeup and varieties of response to diet.

With these caveats in mind:"[more]

Meditation benefits patients with heart disease
"In a study of adults with coronary heart disease (CHD), who were stable and were receiving optimal medical care, 16 weeks of transcendental meditation (TM) not only led to significant reductions in blood pressure, but also improved heart rate variability and insulin resistance, which is associated with an increase risk of diabetes.

These beneficial health effects were achieved without changes in body weight, medication or psychosocial variables, investigators report in the Archives of Internal Medicine...."

Nature Medicine Publication Reports Positive Preclinical Data with Alzheimer's Disease Drug Candidate AZD-103
"AZD-103. The AZD-103 compound is a possible disease-modifying therapeutic drug
candidate for the treatment of Alzheimer's disease. This unique class of drug
candidates may provide significant advantages over the current therapies on
the market. The findings in the Nature Medicine publication show that oral
treatment of AZD-103 (scyllo-cyclohexanehexol) reduces accumulation of amyloid
beta and amyloid beta plaques in the brain, as well as reduces or eliminates
learning deficits in a transgenic mouse model of Alzheimer's disease.
Transition is pursuing the clinical drug development of AZD-103 in an
expedited manner and today, also announced that dosing with AZD-103 has
commenced in Phase I clinical trials......"